Article Details

Chardan Capital Raises Sonnet BioTherapeutics (NASDAQ:SONN) Price Target to $22.00

Retrieved on: 2022-09-23 09:59:42

Tags for this article:

Click the tags to see associated articles and topics

Chardan Capital Raises Sonnet BioTherapeutics (NASDAQ:SONN) Price Target to $22.00. View article details on hiswai:

Excerpt

Finally, Renaissance Technologies LLC increased its stake in shares of Sonnet ... The company develops fully human albumin binding technology, ...

Article found on: www.etfdailynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up